ProMetic last week released Q3 numbers and provided its customary update presentation. Plasminogen is currently stealing most of the headlines, having jumped several hurdles to be used to successfully treat a critically ill baby, and now being prepped to enter clinical trials for the massive chronic wound care market. ProMetic’s partner in this programme has significant expertise on the subject and the presentation showed impressive photos of successful treatment in patients. Meanwhile
17 Nov 2015
Q3 update – Clinical programme gathering steam. More colour on Omnio tie up
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q3 update – Clinical programme gathering steam. More colour on Omnio tie up
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
17 Nov 2015 -
Author:
Derren Nathan -
Pages:
9
ProMetic last week released Q3 numbers and provided its customary update presentation. Plasminogen is currently stealing most of the headlines, having jumped several hurdles to be used to successfully treat a critically ill baby, and now being prepped to enter clinical trials for the massive chronic wound care market. ProMetic’s partner in this programme has significant expertise on the subject and the presentation showed impressive photos of successful treatment in patients. Meanwhile